17687-24-0

Basic information

• Product Name: 5-NITROOROTIC ACID
• Synonyms: 5-NITROOROTIC ACID;2,4-DIHYDROXY-5-NITRO-6-CARBOXYPYRIMIDINE;1,2,3,6-TETRAHYDRO-5-NITRO-2,6-DIOXO-4-PYRIMIDINECARBOXYLIC ACID;NITRO-OROTIC ACID;1,2,3,6-tetrahydro-5-nitro-2,6-dioxopyrimidine-4-carboxylic acid;1,2,3,6-Tetrahydro-5-nitro-2,6-dioxo-4-pyrimidinecarboxylicacid;5-nitro-2,4-dioxo-1H-pyriMidine-6-carboxylic acid;2,6-Dihydroxy-5-nitro-pyrimidine-4-carboxylic acid
• CAS NO: 17687-24-0
• Molecular Formula: C₅H₃N₃O₆
• Molecular Weight: 201.09
• EINECS: 241-671-1
• Mol File: 17687-24-0.mol
• Article Data: 10

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.95g/cm³
• Refractive Index: 1.656
• Storage Temp.: 2-8°C
• PKA: -0.10±0.20(Predicted)
• CAS DataBase Reference: 5-NITROOROTIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 5-NITROOROTIC ACID(17687-24-0)
• EPA Substance Registry System: 5-NITROOROTIC ACID(17687-24-0)

Safety Data

• Hazardous Substances Data: 17687-24-0(Hazardous Substances Data)

Usage

Uses

5-Nitroorotic acid (cas# 17687-24-0) is used in mol. docking predicted selectivity of different classes of antiparasitic plant-derived terpenoid towards Leishmania protein target that was useful in fragment or structure-based antileishmanial drug design and development.

InChI:InChI=1/C5H3N3O6/c9-3-2(8(13)14)1(4(10)11)6-5(12)7-3/h(H,10,11)(H2,6,7,9,12)

Upstream product

• 626-48-2 6-Methyluracil 
• 56-04-2 6-methyl-2-thiouracil 
• 16632-21-6 5-nitro-6-methyluracil 
• 65-86-1 2,4-dihydroxypyrimidine-6-carboxylic acid 
• 154-85-8 orotic acid sodium salt 
• 65-86-1 orotic acid 
• 5435-44-9 (E)-3-Ureido-but-2-enoic acid ethyl ester 

Downstream Products

• 52047-16-2 ethyl 5-nitro-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylate 
• 611-08-5 5-nitrobarbituric acid 
• 52047-13-9 methyl 2,6-dichloro-5-nitro-4-pyrimidinecarboxylate 
• 6311-73-5 methyl 2,6-dihydroxy-5-nitropyrimidine-4-carboxylate 
• 59950-50-4 ethyl 5-amino-2-chloropyrimidine-4-carboxylate 

Relevant articles and documents

Pyrimidine fused ring derivatives and application thereof in medicine

The invention relates to compounds shown in a general formula (I) or stereoisomers, deuterated compounds, solvates, prodrugs, metabolites, pharmaceutically acceptable salts or co-crystal of the compounds, an intermediate and a preparation method of the compounds, and application of the compounds in preparation of drugs for treating diseases related to activity or expression quantity of KRas-G12C.

Method for synthesizing 2-chloro-5-amino-6-pyrimidine ethyl formate

The invention discloses a method for synthesizing 2-chloro-5-amino-6-pyrimidine ethyl formate. The method comprises the following steps: firstly, enabling fuming nitric acid, concentrated sulfuric acid and orotic acid to react so as to obtain nitroorotic acid; further mixing the obtained nitroorotic acid with ethanol, and adding dropwise the concentrated sulfuric acid at room temperature so as toobtain nitroorotic acid ethyl ester; enabling the nitroorotic acid ethyl ester to react with phosphorus oxychloride and an organic alkali so as to obtain 2,4-dichloro-5-nitro-6-pyrimidine ethyl formate; and finally mixing the 2,4-dichloro-5-nitro-6-pyrimidine ethyl formate with palladium carbon and magnesium oxide, putting the mixture into tetrahydrofuran, and performing a reaction, so as to obtain a final product. By adopting the method, the orotic acid in the market is adopted as a raw material, and the 2-chloro-5-amino-6-pyrimidine ethyl formate is prepared through reactions of nitration, esterification, chlorination and reduction. The method is convenient in process operation, simple in operation, gentle in reaction and small in pollution, in addition, the prepared pyrimidine is high in yield and purity and small in environment pollution, and the prepared 2-chloro-5-amino-6-pyrimidine ethyl formate prepared by using the method can be applied to large-scale production.

INHIBITORS OF KRAS G12C MUTANT PROTEINS

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I), or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein B, W, X, Y, R1, R2a, R2b, R3a, R3b, R4a, R4b, G1, G2, m1, m2, L1, L2 and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.